Table 1.
Description of patients and controls
| lcSSc baseline | lcSSc second sample | dcSSc baseline | dcSSc second sample | Controls | |
|---|---|---|---|---|---|
| Number |
40 |
40 |
40 |
40 |
97 |
| Age, years median (range) |
47.5 (16 to 77) |
50 (21 to 81) |
51.5 (22 to 77) |
56 (26 to 80) |
45 (23 to 74) |
| Gender, female:male |
33:7 |
33:7 |
28:12 |
28:12 |
67:30 |
| COMP, U/l median (range) |
9.3 (4.2 to 27.9) |
9.7 (3.9 to 15.8) |
16.0 (6.2 to 37.2) |
10.9 (5.0 to 30.0) |
7.0 (3.2 to 12.1) |
| Disease duration, years median (range) |
1.4 (0.2 to 3.0) |
5.0 (3.2 to 7.1) |
1.0 (0.3 to 3.0) |
4.6 (3.3 to 7.5) |
Not applicable |
| COMP-C3b, AU median (range) |
2.5 (0.4 to 6.4) |
1.9 (0.8 to 6.1) |
2.3 (0.2 to 3.8) |
1.7 (0.7 to 4.0) |
0.6 (0 to 4.4) |
| mRSS median (range) |
5.0 (2.0 to 19.0) |
3.0 (0 to 15.0) |
22.5 (3.0 to 43.0) |
12.5 (0 to 33.0) |
Not applicable |
| CRP, mg/l median (range) |
5.0 (0.8 to 79.0) |
4.0 (0 to 72.0) |
9.9 (0.8 to 91.0) |
4.9 (0.6 to 74.0) |
nd |
| ERS, mm/h median (range) |
11.0 (2.0 to 92.0) |
14.0 (3.0 to 60.0) |
18.0 (4.0 to 50.5) |
20.0 (2.0 to 66.0) |
nd |
| Immunosuppressant AZA:CYC:MTX:MMF |
1:1:1:0 |
12:0:2:3 |
1:2:2:0 |
12:1:2:8 |
|
| Prednisolon, yes:no |
7:32 |
11:28 |
13:25 |
13:25 |
|
| ANA, positive:negative |
31:9 |
|
29:11 |
|
nd |
| ENA, positive:negative |
10:30 |
|
10:30 |
|
nd |
| ACA, positive:negative |
10:30 |
|
1:39 |
|
nd |
| ATA, positive:negative |
3:32 |
|
7:29 |
|
nd |
| 5 unknown |
4 unknown |
||||
| ARA, positive:negative | 0:27 |
6:25 |
nd | ||
| 13 unknown | 9 unknown |
lcSSc, limited cutaneous systemic sclerosis; dcSSc, diffuse cutaneous systemic sclerosis; ACA, anti to centromere antibody; COMP: cartilage oligomeric matrix protein; AU, arbitrary units; mRSS, modified Rodnan skin score; CRP, C-reactive protein; nd, not determined; ERS, erythrocyte sedimentation rate; AZA, azathioprine; CYC, cyclophosphamide; MTX, methotrexate; MMF, mycophenolate mofetil; ANA, antinuclear antibody; ENA, extractable nuclear antigen antibody; ATA, anti-topoisomerase antibody; ARA, anti-RNA polymerase III antibody.